Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
-
Patent number: 9951104Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.Type: GrantFiled: January 7, 2013Date of Patent: April 24, 2018Assignee: Serpin Pharma, LLCInventors: Soren Mogelsvang, Cohava Gelber
-
Patent number: 9951105Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.Type: GrantFiled: June 10, 2016Date of Patent: April 24, 2018Assignee: BIONIZ, LLCInventors: Yutaka Tagaya, Nazli Azimi
-
Patent number: 9943596Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.Type: GrantFiled: November 23, 2015Date of Patent: April 17, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Jimin Lee, Bo Gyou Kim, Seungja Oh, Kyung Ah Kim, Powei Lin, Saet Byoul Lee
-
Patent number: 9945868Abstract: The invention comprises a method for determining degree of modified potency of a bipathic medicament. A bipathic medicine is a medicament comprising a therapeutic component and a homeopathic component, wherein the homeopathic component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated-potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form.Type: GrantFiled: March 18, 2014Date of Patent: April 17, 2018Inventor: Oleg Iliich Epshtein
-
Patent number: 9945798Abstract: The invention comprises a method for determining degree of modified potency of a medicament. A medicine is a medicament comprising a therapeutic component and a homeopathic, i.e., activated-potentiated, component, wherein the activated-potentiated component has some physical, chemical or biological affect on the therapeutic component and/or the pharmacological efficacy thereof. The therapeutic component is biologically related to the starting substance of the homeopathic component. An analytical measurement of at least one characteristic parameter of the therapeutic form is made prior to its interaction with the activated-potentiated form. The same analytical measurement(s) are made and after interaction between the therapeutic and activated-potentiated forms. This data is used to confirm the presence of any modified potency is caused by the presence of molecular form in the activated-potentiated form.Type: GrantFiled: March 18, 2014Date of Patent: April 17, 2018Assignee: Oleg Illiich EpshteinInventor: Oleg Iliich Epshtein
-
Patent number: 9939452Abstract: This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta_11 N-terminal site, i.e. A?11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.Type: GrantFiled: April 29, 2016Date of Patent: April 10, 2018Assignee: JANSSEN PHARMACEUTICA NVInventors: Marc Hubert Mercken, Marc Maria Pierre Vandermeeren
-
Patent number: 9926380Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.Type: GrantFiled: July 3, 2013Date of Patent: March 27, 2018Assignee: Board of Regents, The University of Texas SystemInventors: Jeffrey Molldrem, Anna Sergeeva
-
Patent number: 9926607Abstract: The present invention provides breast cancer markers based on RECQL mutations, and related methods, uses, agents, and kits. The invention includes methods for determining the susceptibility of a subject to developing breast cancer, and methods for detecting, diagnosing, treating, and predicting responses to treatment for breast cancer.Type: GrantFiled: March 23, 2016Date of Patent: March 27, 2018Assignee: Women's College HospitalInventor: Mohammad R. Akbari
-
Patent number: 9925261Abstract: Disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia.Type: GrantFiled: January 26, 2015Date of Patent: March 27, 2018Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: S. Ananth Karumanchi, Sharon Maynard, Vikas P. Sukhatme
-
Patent number: 9925248Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.Type: GrantFiled: August 29, 2014Date of Patent: March 27, 2018Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Kamel Khalili, Wenhui Hu
-
Patent number: 9890144Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.Type: GrantFiled: June 25, 2015Date of Patent: February 13, 2018Assignee: Rigel Pharmaceuticals, Inc.Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
-
Patent number: 9879085Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: April 17, 2017Date of Patent: January 30, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
-
Patent number: 9868777Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.Type: GrantFiled: June 9, 2014Date of Patent: January 16, 2018Assignees: Merck Sharp & Dohme Corp., Board of Regents of the University of Texas SystemInventors: Tong-Ming Fu, Dai Wang, Zhiqiang An
-
Patent number: 9850310Abstract: Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.Type: GrantFiled: September 3, 2015Date of Patent: December 26, 2017Assignee: Janssen Pharmaceutica NVInventors: Francois Gaudet, Jennifer F. Nemeth, Ricardo Attar, Benjamin C. Harman, Yingzhe Li, Jinquan Luo, Ronan McDaid, Steven C. Pomerantz, Susan H. Tam, Alexey Teplyakov, John Wheeler, Sheng-Jiun Wu
-
Patent number: 9822418Abstract: This invention relates to a method of diagnosing a subject as having and/or being a carrier for infantile myofibromatosis. This method involves providing an isolated biological sample from a subject; contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in PDGFRB and/or NOTCH3; detecting, in the sample, the presence or absence of the one or more mutations in PDGFRB and/or NOTCH3 based on said contacting; and diagnosing the subject as having and/or being a carrier for infantile myofibromatosis based on said detecting, where the presence of the one or more mutations in PDGFRB and/or NOTCH3 indicates the subject has a mutation that causes infantile myofibromatosis. Also disclosed is a method of treating a subject having infantile myofibromatosis and a method of preventing or treating symptoms associated with infantile myofibromatosis.Type: GrantFiled: April 22, 2014Date of Patent: November 21, 2017Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: John A. Martignetti, Hakon Hakonarson, Lifeng Tian
-
Patent number: 9822173Abstract: The present application is directed to heterodimeric antibodies and methods of use.Type: GrantFiled: November 21, 2013Date of Patent: November 21, 2017Assignee: AMGEN INC.Inventors: Gunasekaran Kannan, Monica Florio, Zhi Liu, Wei Yan
-
Patent number: 9809648Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.Type: GrantFiled: December 17, 2012Date of Patent: November 7, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
-
Patent number: 9809636Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.Type: GrantFiled: March 14, 2013Date of Patent: November 7, 2017Assignee: ACCELERON PHARMA INC.Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
-
Patent number: 9796984Abstract: The present invention relates to genes, proteins and methods comprising molecules that alter amino acid levels. In one embodiment, the present invention relates to altering guanidino substrate hydrolysis activities in plants, arthropods and microorganisms using molecules within the arginase family and other molecules that alter an amino acid levels. In ones embodiment, the present invention relates to altering threonine substrate deamination and dehydration activities in plants, arthropods and microorganisms using molecules within the threonine deaminase family and other molecules that alter amino acid levels. In one embodiment, the present invention relates to using genes, proteins and methods comprising arginase or threonine deaminase for altering the pathophysiology of plants, arthropods and microorganisms. In a preferred embodiment, the present invention relates to altering guanidino substrate hydrolysis activity in plants, arthropods, and microorganisms using arginase.Type: GrantFiled: September 18, 2014Date of Patent: October 24, 2017Assignee: Board of Trustees of Michigan State UniversityInventors: Gregg A. Howe, Hui Chen
-
Patent number: 9790277Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.Type: GrantFiled: December 23, 2013Date of Patent: October 17, 2017Assignees: The Johns Hopkins University, MedImmune, LLCInventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen
-
Patent number: 9782428Abstract: Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.Type: GrantFiled: March 18, 2014Date of Patent: October 10, 2017Assignee: Northeastern UniversityInventors: Michail V. Sitkovsky, Robert Koehler Abbott, Stephen Matthew Hatfield
-
Patent number: 9770486Abstract: Disclosed are novel methods for preventing or attenuating neuronal damage or stimulating neuronal repair, prior to or following central nervous system injury associated with acute or chronic nervous system injury. Macrophage colony stimulating factor receptor agonists including macrophage colony stimulating factor (M-CSF or CSF-1), interleukin-34 (IL-34), proteins or biologically active fragments thereof, peptides or biologically active fragments thereof, peptidomimetics, or small molecules, and the like are effective for prevention or treatment of acute nervous system injury or chronic nervous system injury involving Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and the like.Type: GrantFiled: September 9, 2015Date of Patent: September 26, 2017Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Department of Veterans AffairsInventors: Jian Luo, Anton Wyss-Coray
-
Patent number: 9771570Abstract: The present invention relates to isolated polypeptides having protease activity and isolated nucleic acid sequences encoding the proteases. The invention also relates to nucleic acid constructs, vectors, and host cells, including plant and animal cells, comprising the nucleic acid sequences, as well as methods for producing and using the proteases, in particular the use of the proteases in animal feed.Type: GrantFiled: September 5, 2013Date of Patent: September 26, 2017Assignee: Novozymes A/SInventors: Mary Ann Stringer, Tine Hoff, Peter Rahbek Oestergaard, Katrine Pontoppidan
-
Patent number: 9745367Abstract: A method of selecting a genus of therapeutic antibodies includes selecting antibodies with the following criteria; a) do inhibit cell lysis under conditions wherein the alternative pathway is isolated from the classical pathway; and b) do not inhibit cell lysis under conditions wherein the classical pathway is isolated from the alternative pathway; and c) do not inhibit cell lysis under conditions wherein the classical pathway and alternative pathway are active; and d) do inhibit C3b produced exclusively by the alternative pathway.Type: GrantFiled: October 5, 2012Date of Patent: August 29, 2017Assignee: Novelmed Theraputics, Inc.Inventor: Rekha Bansal
-
Patent number: 9724413Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.Type: GrantFiled: August 1, 2012Date of Patent: August 8, 2017Assignee: Genentech, Inc.Inventors: Heather Maecker, Bryan Irving
-
Patent number: 9719981Abstract: The present invention provides methods of treating Alport syndrome in a subject by the administration of an agent that can block the activation of RAC1/CDC42 members of the rho family of small GTPases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1. Such administration prevents invasion of the glomerular capillary tufts by mesangial lamellipodial/filopodial processes, blocks mesangial process invasion abrogates the deposition of laminin 211 in the GBM, and prevents the activation of maladaptive expression of proteins known to contribute to glomerular disease progression.Type: GrantFiled: December 23, 2014Date of Patent: August 1, 2017Assignee: Father Flanagan's Boys' HomeInventor: Dominic Cosgrove
-
Patent number: 9719135Abstract: This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2— peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease.Type: GrantFiled: July 2, 2015Date of Patent: August 1, 2017Assignee: MANNIN RESEARCH INC.Inventor: Susan E. Quaggin
-
Patent number: 9708661Abstract: The present invention relates to methods, monitors and systems, useful, for example, for advanced detection of sepsis in a subject.Type: GrantFiled: June 18, 2015Date of Patent: July 18, 2017Assignee: Becton, Dickinson and CompanyInventors: Song Shi, Richard L. Moore, James Garrett
-
Patent number: 9689039Abstract: Presented herein are biomarkers related to lung cancer. The presently identified salivary biomarkers create the basis for a lung cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed lung cancer assay in clinical, diagnostic and therapeutic uses is also included.Type: GrantFiled: February 10, 2011Date of Patent: June 27, 2017Assignee: The Regents of the University of CaliforniaInventors: David T. Wong, Lei Zhang, Hua Xiao, Hui Zhou
-
Patent number: 9688746Abstract: The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.Type: GrantFiled: December 4, 2013Date of Patent: June 27, 2017Assignee: Canimguide Therapeutics ABInventors: Leif Håkansson, Birgitta Clinchy
-
Patent number: 9683235Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.Type: GrantFiled: July 21, 2014Date of Patent: June 20, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Patent number: 9676856Abstract: Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-HrCR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and/or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.Type: GrantFiled: August 11, 2014Date of Patent: June 13, 2017Assignee: The Johns Hopkins UniversityInventor: Lieping Chen
-
Patent number: 9663580Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: October 13, 2016Date of Patent: May 30, 2017Assignee: HOFFMANN-LA ROCHE INC.Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
-
Patent number: 9650438Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: February 24, 2015Date of Patent: May 16, 2017Assignee: Novartis AGInventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
-
Patent number: 9644003Abstract: The present invention relates to a RTN4B-related polypeptide, a monoclonal antibody thereof, a monoclonal antibody-producing hybridoma cell strain, and, preparation and applications thereof. The RTN4B polypeptide comprises an amino acid sequence presented by SEQ ID NO: 1. The invention further discloses a monoclonal antibody, a hybridoma cell strain to produce the monoclonal antibody prepared by the RTN4B polypeptide, and the related application in the treatment or prevention of tumors thereof.Type: GrantFiled: May 6, 2013Date of Patent: May 9, 2017Assignee: FUDAN UNIVERSITYInventors: Long Yu, Guoqing Ji, Dingding Han, Yanhua Wu, Lisha Tang
-
Patent number: 9636334Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.Type: GrantFiled: May 1, 2015Date of Patent: May 2, 2017Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: Sarah L. Pogue, David S. Wilson, Anthony Gerard Doyle, Collette Jane Behrens
-
Patent number: 9637535Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.Type: GrantFiled: March 14, 2014Date of Patent: May 2, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie Orengo
-
Patent number: 9624285Abstract: A composition of matter is disclosed which comprises isolated oligomers of human islet amyloid polypeptide (IAPP). Antibodies recognizing same are also disclosed. Use of the composition of matter and the antibodies are also disclosed.Type: GrantFiled: June 2, 2011Date of Patent: April 18, 2017Assignee: Ramot a Tel-Aviv University Ltd.Inventors: Yaron Bram, Ehud Gazit
-
Patent number: 9617338Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.Type: GrantFiled: November 17, 2016Date of Patent: April 11, 2017Assignee: Kymab LimitedInventors: Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
-
Patent number: 9605063Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.Type: GrantFiled: November 13, 2014Date of Patent: March 28, 2017Assignee: Glaxo Group LimitedInventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
-
Patent number: 9594083Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.Type: GrantFiled: September 27, 2013Date of Patent: March 14, 2017Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris DescartesInventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
-
Patent number: 9550828Abstract: A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.Type: GrantFiled: September 5, 2014Date of Patent: January 24, 2017Assignee: Boise State UniversityInventors: Cheryl Jorcyk, Dong Xu
-
Patent number: 9550829Abstract: The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.Type: GrantFiled: March 13, 2014Date of Patent: January 24, 2017Assignee: Genentech, Inc.Inventors: Dorothy French, Erik Huntzicker, Christian W. Siebel
-
Patent number: 9533041Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.Type: GrantFiled: December 5, 2011Date of Patent: January 3, 2017Assignee: Institut National de la Santé et de la Recherche MédicaleInventor: Frédéric Jaisser
-
Patent number: 9511117Abstract: The present invention provides methods for improving muscular function or treating a muscular disorder in an individual by administering to the individual a pharmacologically effective amount of a compound that inhibits microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production. In addition compounds that block sarcolemmal Ca2+ channel activation and/or renin-angiotensin signaling may be administered with the inhibitor of microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production.Type: GrantFiled: May 22, 2014Date of Patent: December 6, 2016Assignee: University of Maryland, BaltimoreInventors: Christopher W. Ward, Ramzi Khairallah
-
Patent number: 9512225Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.Type: GrantFiled: June 22, 2016Date of Patent: December 6, 2016Assignee: Yeda Research and Development Co. LtdInventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
-
Patent number: 9506066Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.Type: GrantFiled: December 2, 2014Date of Patent: November 29, 2016Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Joyce Eskdale, Rachael Siegel
-
Patent number: 9499625Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: March 6, 2015Date of Patent: November 22, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
-
Patent number: 9498543Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: March 12, 2014Date of Patent: November 22, 2016Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
-
Patent number: 9499612Abstract: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.Type: GrantFiled: July 25, 2012Date of Patent: November 22, 2016Assignee: Glaxo Group LimitedInventors: Claire Ashman, Ian Richard Catchpole, Zoe Hughes-Thomas, Alan Peter Lewis, Michael Steward